


SMMML newsletter

April 2025

Based on data from December 2024–March 2025

Monthly updates around multiple myeloma

MMsyndiTrack™



The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.



Who will benefit from this newsletter?


Any professionals interested in keeping up with developments around multiple myeloma:

- Marketers
- Business Analysts
- But also HCPs who want to anticipate the future landscape of MM management




Introduction on Multiple Myeloma

What is Multiple Myeloma?



70
YEARS



Read more on Multiple Myeloma:



→ [Professional version in English](#)


→ [Professional version in French](#)



→ [Consumer version in English](#)

→ [Consumer version in French](#)

MM lines of therapy based on to the following definitions



1st line Induction prior SCT


For stem cell candidates, the first step to gain a response to reduce the tumor burden before SCT. Please note that patients who received more than one SCT are considered to be in "1st line prior to stem cell transplant" for the latest SCT procedure planned. For instance, should a patient receive an induction treatment prior to a 2nd SCT, he should be considered as a 1st line transplant patient.

1st line Consolidation post SCT

1st line therapy **after** stem cell transplant to **deepen the response** achieved by adding a **short course** of full dose therapy.

1st line Maintenance post SCT




1st line therapy **after** stem cell transplant to **sustain the quality of the response** achieved by adding a long course – from several months up to disease progression – of reduced dose therapy.



MM treatment history timeline



- IMiDs
- PIs
- IMS
- Mabs
- HDACi
- SINE
- BCMA
- CAR-T
- BisAbs



Confidential



16+
YEARS

17+
COUNTRIES OVER TIME

UP
TO **90**
HCPs
per wave
per country

UP
TO **4**
WAVES
per year

4,5k
PATIENTS CHARTS
per wave

18k
PATIENTS CHARTS
per year (in EU5)

What's new **MMsyndiTrack™**

Launching of a US pilot wave, Why ?

- Needs from Pfizer and GSK for MM US data
- Back data for EU5 for 15 years
- MM US market changing fast
- Different needs in the US market for labs (patients' ethnicity treatments gap as an example)

→ **Co-funding with GSK for Q4 2022**

APLUSA's added value

- Quarterly + month to month data collection (our competitors → only quarterly data)
- Market adaptability: adjusting our questionnaires and updating the list of treatments by including market trends on a monthly basis → **new CAR-Ts + BisAbs**
- Patient's full treatment history
- Deliverables with Power BI DID



December 2024 – March 2025



● CONTENTS

01.

News around clinical trials in phase II

- Phase II Line 1: Triplet/Quadruplet Therapies
- Phase II Line 1: Bispecific Therapies
- Phase II R/R: CAR-T

02.

News around clinical trials in Phase III

- Phase III Line 1: Quadruplet Therapies
- Phase III R/R: Doublet Therapy
- Phase III R/R: Triplet Therapy
- Phase III R/R: CAR-T

03.

Themes of discussion : HCPs

- SOV Themes of discussion
- Posts driving most engagement
- Focus on ASH 2024

04.


News articles overtime

- Volume of articles per volume of mentions
- Articles per themes

05.

Market watch

- **Market watch:**
 - December 2024
 - January 2025
 - February 2025
 - March 2025



● SCOPE



The scope of the analysis is focused on mentions coming **worldwide**.*




There were a total of **36K** mentions recorded during the listening period from **December 1st, 2024**, to **March 31st, 2025**.



A majority of mentions came from **X (formerly Twitter) (57%)**, **News (42%)**, and **Reddit (1%)**.

*myeloma OR multiplemyeloma OR #mmsm
OR #Myeloma* OR #Curemyeloma* OR
#mmmrd OR #mmsm OR title: ("multiple
myeloma" OR myeloma)

Methodology



Sponsor	Trial name + link (ctrl + right click)	Line of treatment	Combination/Monotherapy being studied	Note
AbbVie	NCT03314181	RR	venetoclax, daratumumab and dexamethasone (With and Without Bortezomib)	
Bristol-Myers Squibb	ELOQUENT-3	RR	Elotuzumab, pomalidomide, dexamethasone	
CARsgen Therapeutics	LUMMICAR-2	RR	Monotherapy: zevorcabtagene autoleucl	
Celgene	NCT03989414	1L/RR	bortezomb, dexamethasone, daratumumab, elotuzumab, isatuximab, carfilzomib	
	NCT03989414	IL/RR	mezigdomide, bortezomib, dexamethasone, daratumumab, carfilzomib, elotuzumab, isatuximab	
	KarMMa-2	RR	Monotherapy (one arm with lenalidomide) ; BMTCTN1902: Monotherapy: Idecabtagene vicleucl	
	NCT03374085	RR	Monotherapy: mezigdomide or in combination with dexamethasone	
Cellular Biomedicine Group	NCT05521802	RR	Monotherapy: C-CAR088	
GSK	DREAMM-2	RR	Monotherapy: blenrep	
Janssen	GRIFFIN	1L	daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd)	
	CARTITUDE-1	RR	Monotherapy: ciltacabtagene autoleucl	
	CARTITUDE-2	RR	Monotherapy: ciltacabtagene autoleucl	
	MajesTEC-1	RR	Monotherapy: teclistamab	
	MonumenTAL-1	RR	Monotherapy: talquetamab	
	RedirectTT-1	RR	teclistamab, talquetamab, daratumumab	
Kite, a Gilead company	iMMagine-1	RR	Monotherapy: anitocabtagene autoleucl	
Nanjing IASO Biotechnology	FUJMANBA-1	RR	Monotherapy: equecabtagene autoleucl	
Nexcella	NCT04720313	RR	Monotherapy: NXC-201	
Pfizer	MagnetisMM-3	RR	Monotherapy: elranatamab	
	MagnetisMM-9	RR	Monotherapy: elranatamab or in combination with dexamethasone	
Regeneron	LINKER-MM1	RR	Monotherapy: Linvoseltamab (also known as REGN5458)	
Other	FORTE	1L	carfilzomib, lenalidomide, daratumumab, dexamethasone	Sponsor: Mario Boccadoro, University of Turin, Italy
	NCT05123131	1L	isatuximab, bortezomib, lenalidomide, dexamethasone	Sponsor: Cancer Trials Ireland
	NCT02969837	1L	elotuzumab, carfilzomib, lenalidomide, dexamethasone	Sponsor: University of Chicago
	NCT03590652	RR	daratumumab, ixazomib, pomalidomide, dexamethasone	Sponsor: University of California, San Diego
	NCT04309981	RR	Monotherapy: cesnicabtagene autoleucl (ARI0002h)	Sponsor: Sara V. Latorre
	REBUILD	RR	Monotherapy: daratumumab	Sponsor: Hellenic Society of Hematology
	NCT06105554	RR	belumosudil mesylate with or without dexamethasone	Sponsor: M.D. Anderson Cancer Center
	Cardamon	/	cyclophosphamide, dexamethasone, carfilzomib	Sponsor: University College, London
	MASTER	/	dexamethasone, lenalidomide, daratumumab, carfilzomib	Sponsor: University of Alabama at Birmingham



Phase II Line 1 Triplet/Quadruplet Therapies: teclistamab-cqyv demonstrates potential as frontline combination therapy.



Headlines/Hot off the press

“ **teclistamab-cqyv demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma** ”

“100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy”
Click [here](#) to read the full article

MajesTEC-5

Ctrl + click to access clinical trial:
[NCT05695508](#)

“Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab- and Talquetamab-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma”



Sponsor



Combination

**teclistamab + bortezomib + lenalidomide
+ daratumumab + dexamethasone**





Headlines/Hot off the press

“ **Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma** ”

"Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM)."

Click [here](#) to read the full article

“ **Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma** ”

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License Application for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025."

Click [here](#) to read the full article

Sponsor

REGENERON®

LINKER-MM1

Ctrl + click to access clinical trial : [NCT03761108](#)

"Phase 1/2 Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma"



Molecule

linvoseltamab






Phase II Relapse/Refractory CAR-T: Arcellx Announces New Positive Data for Its iMMagine-1 study.



Clinical trial mentioned/Sponsor

iMMagine-1



FUMANBA-1



Headlines/Hot off the press

“ Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition ”

“Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months”

Click [here](#) to read the full article

“ IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH ”

“today shared findings via a poster presentation of the results on the impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma(R/RMM) with Equecabtagene Autoleucel (Eque-cel, FUCASO) at the 66th American Society of Hematology (ASH) Annual Meeting.

Click [here](#) to read the full article

iMMagine-1

Ctrl + click to access clinical trial:

NCT05396885

“Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)”

FUMANBA-1

Ctrl + click to access clinical trial: **NCT05066646**

“A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma”

Molecules

anitocabtagene autoleucel

equecabtagene autoleucel



Phase II N= 1 048 mentions
Social media listening period: December 2024-March 2025
Scope: worldwide in English

Sponsor	Trial name + link (ctrl + right click)	Line of treatment	Combination/Monotherapy being studied	Note
AbbVie	Bellini	RR	venetoclax, bortezomib, dexamethasone	
	CANOVA	RR	venetoclax, dexamethasone	
Celgene	DETERMINATION	RR	lenalidomide, bortezomib, dexamethasone	
	KarMMa-3	RR	Monotherapy: Idecabtagene vicleucel	
GSK	DREAMM-3	RR	Monotherapy: belantamab mafodotin	
	DREAMM 7	RR	belantamab mafodotin, bortezomib and dexamethasone	
	DREAMM 8	RR	belantamab mafodotin Plus pomalidomide and dexamethasone	
Janssen	AURIGA	Maintenance	daratumumab, lenalidomide	
	CARTITUDE-4	RR	Monotherapy: ciltacabtagene autoleucel	
	CASTOR	RR	daratumumab, bortezomib, dexamethasone	
	MAIA	1L	daratumumab, lenalidomide, dexamethasone	
	MajesTEC-3	RR	teclistamab, daratumumab Subcutaneously (SC) (Tec-Dara)	
	POLLUX	RR	daratumumab, lenalidomide, and dexamethasone	
Karyopharm	BOSTON	RR	selinexor, bortezomib,, dexamethasone	
Oncopeptides	OCEAN	RR	Monotherapy: melphalan flufenamide	
Pfizer	MagnetisMM-5	RR	Monotherapy: elranatamab or doublet therapy with daratumumab	
Sanofi	IMROZ	1I	isatuximab, bortezomib, lenalidomide dexamethasone	
	IRAKLIA	1I	Pomalidomide, isatuximab, dexamethasone	
	ICARIA-MM	RR	isatuximab, pomalidomide, dexamethasone	
	IKEMA	RR	isatuximab, carfilzomib And dexamethasone	
Takeda	TOURMALINE-MM1	RR	ixazomib, lenalidomide, dexamethasone	
	TOURMALINE-MM2	1L	ixazomib, lenalidomide, dexamethasone	
Other	ATLAS	Maintenance	lenalidomide, carfilzomib, dexamethasone	Sponsor: University of Chicago
	BENEFIT	1L	isatuximab, lenalidomide, dexamethasone	Sponsor: Poitiers University Hospital
	DRAMMATIC	/	lenalidomide, daratumumab	Sponsor: SWOG Cancer Research Network
	EQUATE	1L	daratumumab, bortezomib, lenalidomide, dexamethasone	Sponsor: ECOG-ACRIN Cancer Research Group
	GMMG HD7	1L	Isatuximab, lenalidomide, bortezomib, dexamethasone	Sponsor: University of Heidelberg Medical Center
	IsKia	1L	isatuximab, lenalidomide, carfilzomib, dexamethasone	Sponsor: European Myeloma Network
	Myeloma XI	1L	cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib	Sponsor: University of Leeds




Phase III Line 1 Quadruplet Therapies: sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients.



Clinical trial mentioned/Sponsor

CEPHEUS
janssen



IMROZ
sanofi



IMROZ

Ctrl + click to access
clinical trial:

[NCT03319667](#)

"A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant"

CEPHEUS

Ctrl + click to access clinical
trial: [NCT03652064](#)

"The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone."

Headlines/Hot off the press

“ daratumumab SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis ”
[Click here](#) to read the full article

“ daratumumab subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility ”
[Click here](#) to read the full article

“ ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed mm patients ”
[Click here](#) to read the full article

“ Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma ”
[Click here](#) to read the full article

“ China NMPA approves Sanofi's Sarclisa for patients with newly diagnosed multiple myeloma ”
[Click here](#) to read the full article

“ EMA committee approves Sanofi's Sarclisa in combination with VRd for newly diagnosed MM ”
[Click here](#) to read the full article

Combinations

isatuximab + dexamethasone
+ lenalidomide + bortezomib

daratumumab +
+ dexamethasone
+ lenalidomide + bortezomib





Phase III Relapse/Refractory Doublet Therapy: teclistamab demonstrates potential as frontline combination therapy.



Headlines/Hot off the press

“ **TECVAYLI®(teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma** ”

“100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy”
Click [here](#) to read the full article

Sponsor



MajesTEC-4
Ctrl + click to access clinical trial:
[NCT05243797](#)

“This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.”



Combinations

teclistamab + daratumumab






Phase III Relapse/Refractory Triplet Therapy: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study.



Clinical trial mentioned/Sponsor

Headlines/Hot off the press

DREAMM-7



IRAKLIA
sanofi



IRAKLIA

Ctrl + click to access the clinical trial : [NCT05405166](#)

"This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI)."

DREAMM-7

Ctrl + click to access clinical trial: [NCT04246047](#)

"A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma"

“ New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma ”

Click [here](#) to read the full article

“ ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients ”

Click [here](#) to read the full article

“ Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse ”

Click [here](#) to read the full article

“ FDA Reviews Belantamab Mafodotin for Approval in Relapsed/Refractory Multiple Myeloma ”

Click [here](#) to read the full article

“ China reviews Blenrep combo for multiple myeloma treatment ”

Click [here](#) to read the full article

Combinations

pomalidomide + isatuximab
+ dexamethasone

belantamab mafodotin
+ bortezomib
+ dexamethasone





Phase III Relapse/Refractory CAR-T: ciltacabtagene autoleucel demonstrated significantly higher rates of minimal residual disease negativity



Headlines/Hot off the press

“ **CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) demonstrated significantly higher rates of minimal residual disease negativity compared to standard therapies in the CARTITUDE-4 study** ”

“89 percent of patients evaluable for minimal residual disease (MRD) assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months”

Results add to the overall survival (OS) benefits recently presented, as the first cell therapy to significantly extend OS versus standard therapies in multiple myeloma”

Click [here](#) to read the full article

Sponsor



CARTITUDE-4

Ctrl + click to access clinical trial: [NCT04181827](#)

“A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma”



Molecule

ciltacabtagene autoleucel




Phase III N= 2 522 mentions



Social media listening period: December 2024-March 2025

Scope: worldwide in English

SOV topics of conversations



SOV molecules



Dr Al Hadidi share an algorithm for therapeutic anticoagulation for cancer associated VTE. This was lifted from an ASH 2024 educational articles.

Dr Banerjee shared his thoughts on a paper discussing the risk of enteric T-cell lymphoma with cilta-cel CAR integration into the TP53 locus. Dr Banerjee shared that while this risk is minimal, those findings will inform his communication with patients going forward.

Dr Costa shared the international myeloma working group immunotherapy committee recommendation for sequencing immunotherapy in the treatment of multiple myeloma.

Most engagement


Most retweeted, liked and replied to (Ctrl + right click to access posts)



Samer Al Hadidi, MD, MS, FACP
@HadidiSamer

#ASH24 #mmsm @ASH_hematology

Nice algorithm for therapeutic anticoagulation for cancer associated VTE



Rahul Banerjee, MD, FACP
@RahulBanerjeeMD

1/ Sobering but important work in @NEJM by @MScordoMD @szusmani et al: fatal case of enteric T-cell lymphoma following cilta-cel (#MMsm CAR-T) CAR integration into the TP53 locus.

One of few papers that informs clinical discussions the moment it comes out. My two takeaways:

The NEW ENGLAND JOURNAL of MEDICINE

BRIEF REPORT

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53



Luciano J Costa
@End_myeloma

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia



The **AQUILA** study was by far the most discussed clinical trial pertaining to multiple myeloma.

The portion of the study presented at ASH were focused on smouldering multiple myeloma and evaluated whether daratumumab provided superior outcomes than the current standard of care.


Volume of mentions




Topics of discussions (type of treatment)






Most mentioned clinical trials



Most mentioned molecules




Top posts from HCPs per engagement



Media (press releases): volume and articles per peak



Volume of articles overtime



A "I was told I couldn't have an Afro wig after chemo" [LINK](#)

"Celebrating innovation happens from the inside out" [LINK](#)

"The **Multiple Myeloma Research Foundation (MMRF)** Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple Myeloma" [LINK](#)

"Genes Highlight Who'll Benefit From Multiple Myeloma Treatment With **Venclexta**" [LINK](#)

B "ASH: **Sarclisa** combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients" [LINK](#)

"**Belantamab Mafodotin** shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse" [LINK](#)

"Poseida Therapeutics Highlights Positive Interim Phase 1 Results for **P-BCMA-ALLO1** and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting" [LINK](#)


"GSK : **Blenrep** (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma Form 6 K" [LINK](#)

B continued "High-Fiber Diet May Prevent a Blood Cancer in People at High Risk" [LINK](#)


"Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows" [LINK](#)

"**DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)**-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma" [LINK](#)

Media (press releases): volume and articles per peak



Volume of articles overtime



C "Woman climbs Kilimanjaro after life-changing blood cancer diagnosis" [LINK](#)

"**Simcere Zaiming and AbbVie** Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma" [LINK](#)

"**Sarclisa** obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma" [LINK](#)

D "**HealthTree** Foundation Announces Real-World Data Awards for 2024" [LINK](#)

"**Isatuximab** Plus VRd Wins Japanese Approval for Newly Diagnosed Myeloma" [LINK](#)

D continued "**IASO** Bio Announces Acceptance of New Drug Application for **Equecabtagene Autoleucel** (FUCASO) by the Singapore Health Sciences Authority (HSA)" [LINK](#)

"**Kangpu Biopharmaceuticals** Received **IND Approval** from NMPA for **KPG-818** to Treat Relapsed/Refractory Multiple Myeloma" [LINK](#)

"**Sarclisa** gains new approval in Japan" [LINK](#)

E "**DARZALEX** Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight" [LINK](#)

"The **International Myeloma Foundation** Announces 2nd Annual Iceland Cycling Expedition, to be Held from August 27 – September 2" [LINK](#)

E continued "**CARVYKTI** Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight" [LINK](#)


"**Arcellx** CMO Discusses Novel Investigational **CAR-T Therapy** During Multiple Myeloma Awareness Month" [LINK](#)

"**2seventy bio** Enters into Definitive Agreement to be Acquired by **Bristol Myers Squibb**" [LINK](#)

"Inc. Names **HealthTree** CEO **Jenny Ahlstrom** to Its 2025 Female Founders 500 List" [LINK](#)

"**HealthTree** Foundation Launches **AI-Powered** Personalized Clinical Trial Finder" [LINK](#)

"Indonesia approves **Antengene's Xpovio** NDA for multiple indications" [LINK](#)



Associations/foundations

- "The **Multiple Myeloma Research Foundation (MMRF)** Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple Myeloma" [LINK](#)
- "**HealthTree** Foundation Announces Real-World Data Awards for 2024" [LINK](#)
- "The **International Myeloma Foundation** Announces 2nd Annual Iceland Cycling Expedition, to be Held from August 27 – September 2" [LINK](#)
- "Inc. Names **HealthTree** CEO **Jenny Ahlstrom** to Its 2025 Female Founders 500 List" [LINK](#)
- "**HealthTree** Foundation Launches **AI-Powered** Personalized Clinical Trial Finder" [LINK](#)

Antibody-drug conjugates (BCMA)

- "**Belantamab Mafodotin** shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse" [LINK](#)
- "GSK : **Blenrep** (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma Form 6 K" [LINK](#)
- "**DARZALEX FASPRO®** (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma" [LINK](#)
- "**DARZALEX** Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight" [LINK](#)

CART

- "**CARVYKTI** Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight" [LINK](#)
- "**Arcellx** CMO Discusses Novel Investigational **CAR-T** Therapy During Multiple Myeloma Awareness Month" [LINK](#)
- "**IASO** Bio Announces Acceptance of New Drug Application for **Equecabtagene Autoleucel** (FUCASO) by the Singapore Health Sciences Authority (HSA)" [LINK](#)
- "Poseida Therapeutics Highlights Positive Interim Phase 1 Results for **P-BCMA-ALLO1** and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting" [LINK](#)

B-cell lymphoma 2 (BCL-2)

- "Genes Highlight Who'll Benefit From Multiple Myeloma Treatment With **Venclexta**" [LINK](#)

Business

"**2seventy bio** Enters into Definitive Agreement to be Acquired by **Bristol Myers Squibb**" [LINK](#)

Monoclonal antibody against CD38 (Mabs)

- "**Sarclisa** obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma" [LINK](#)
- "**Isatuximab** Plus VRd Wins Japanese Approval for Newly Diagnosed Myeloma" [LINK](#)
- "ASH: **Sarclisa** combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients" [LINK](#)
- "**Sarclisa** gains new approval in Japan" [LINK](#)

Nuclear export inhibitor (SINE)

- "Indonesia approves **Antengene's Xpovio** NDA for multiple indications" [LINK](#)

Patient life

- "I was told I couldn't have an Afro wig after chemo" [LINK](#)
- "Celebrating innovation happens from the inside out" [LINK](#)
- "Woman climbs Kilimanjaro after life-changing blood cancer diagnosis" [LINK](#)
- "**High-Fiber Diet** May Prevent a Blood Cancer in People at High Risk" [LINK](#)
- "Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows" [LINK](#)

Small molecule immunomodulator of Cereblon (CRBN)

- "**Kangpu Biopharmaceuticals** Received **IND Approval** from NMPA for **KPG-818** to Treat Relapsed/Refractory Multiple Myeloma" [LINK](#)

Trispecific Antibody

"**Simcere Zaiming and AbbVie** Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Confidential Multiple Myeloma" [LINK](#)



Drug Market Watch

December 2024



“FDA Reviews **Belantamab Mafodotin** for Approval in Relapsed/Refractory Multiple Myeloma [LINK](#)”



Drug Market Watch

January 2025



GAZZETTA UFFICIALE
DELLA REPUBBLICA ITALIANA

“Oncopeptides’ **Pepaxti** formally approved”
for full reimbursement in Italy [LINK](#)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

“**Sarclisa** approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma [Link](#)”



国家药品监督管理局
National Medical Products Administration

“**Sarclisa** obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma [LINK](#)”



“IASO Bio Announces Acceptance of New Drug Application for **Equecabtagene Autoleucel** (FUCASO) by the Singapore Health Sciences Authority (HSA) [LINK](#)”

Drug Market Watch

February 2025

NICE

National Institute for
Health and Care Excellence

“ Sanofi’s Push for Pricing Flexibility in the UK [LINK](#) ”



“ Japanese MHLW approves **Sarclisa** for patients with newly diagnosed multiple myeloma [Link](#) ”



“ Antengene Announces **XPOVIO**® Approved for Public Health Insurance Coverage in Taiwan Market [LINK](#) ”



“ **Linvoseltamab** BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma [LINK](#) ”

“ FDA Grants **OPN-6602** Orphan Drug Status in R/R Myeloma [LINK](#) ”

“ FDA Approves Second Biosimilars for Prolia/**Xgeva** [LINK](#) ”

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

“ **Linvoseltamab** Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma [Link](#) ”

“ Johnson & Johnson’s **DARZALEX**® (**daratumumab**) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility [LINK](#) ”



国家药品监督管理局
National Medical Products Administration

“ Sanofi’s **Sarclisa** combo approved in China for multiple myeloma [LINK](#) ”

“ Kangpu Biopharmaceuticals Received IND Approval from NMPA for **KPG-818** to Treat Relapsed/Refractory Multiple Myeloma [LINK](#) ”



Drug Market Watch

March 2025



“Indonesia approves Antengene’s **Xpovio** NDA for multiple indications”
[LINK](#)”